PFE - Pfizer Stock

Market Summary

USD33.62-0.37

Market Closed

-1.09%

PFE Alerts

Big fall in Revenue (Y/Y)
Big fall in earnings (Y/Y)

PFE Stock Price

PFE RSI Chart

PFE Valuation

Market Cap

189.8B

Price/Earnings (Trailing)

8.84

Price/Sales (Trailing)

2.44

EV/EBITDA

6.16

Price/Free Cashflow

17.8

PFE Price/Sales (Trailing)

PFE Profitability

EBT Margin

34.37%

Return on Equity

28.77%

Return on Assets

14.82%

Free Cashflow Yield

5.62%

PFE Fundamentals

PFE Revenue

Revenue (TTM)

77.9B

Revenue Y/Y

-54.1%

Revenue Q/Q

-30.35%

PFE Earnings

Earnings (TTM)

21.5B

Earnings Y/Y

-76.51%

Earnings Q/Q

-58.02%

Price Action

52 Week Range

33.4454.93

(Low)(High)

Last 7 days

-1.3%

Last 30 days

-9.2%

Last 90 days

-13.2%

Trailing 12 Months

-24.3%

PFE Financial Health

Current Ratio

1.37

PFE Investor Care

Dividend Yield

4.85%

Dividend/Share (TTM)

1.63

Shares Dilution (1Y)

0.95%

Diluted EPS (TTM)

3.76

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Get all data in R, Python etc through our Historical Stock Data APIs

Latest Insider Trading transactions for PFE

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
2023-05-31	Denton David M	sold (taxes)	-616,798	38.02	-16,223	chief financial officer & evp
2023-05-08	Gottlieb Scott	bought	38,580	38.58	1,000	-
2023-05-05	Gottlieb Scott	bought	38,425	38.425	1,000	-
2023-03-31	Pao William	sold (taxes)	-901,476	40.8	-22,095	executive vice president
2023-03-15	DAMICO JENNIFER B.	sold	-396,678	40.02	-9,912	svp & controller
2023-02-27	SAHNI PAYAL	sold (taxes)	-52,891	40.78	-1,297	executive vice president
2023-02-27	McDermott Michael	sold (taxes)	-125,643	40.78	-3,081	executive vice president
2023-02-27	DAMICO JENNIFER B.	sold (taxes)	-58,193	40.78	-1,427	svp & controller
2023-02-25	SAHNI PAYAL	acquired	204,202	22.89	8,921	executive vice president
2023-02-25	LANKLER DOUGLAS M	sold (taxes)	-1,101,740	41.75	-26,389	executive vice president

Which funds bought or sold PFE recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
2023-09-19	BIRMINGHAM CAPITAL MANAGEMENT CO INC/AL	reduced	-7.91	-995,067	4,785,640	2.00%
2023-09-18	CAPE ANN SAVINGS BANK	added	4.7	-40,824	654,775	0.44%
2023-09-15	CJM Wealth Advisers, Ltd.	sold off	-100	-284,577	-	-%
2023-09-14	IMS Capital Management	added	22.05	264,254	2,980,970	1.66%
2023-09-13	CGC Financial Services, LLC	new	-	72,746	72,746	0.05%
2023-09-12	DCM Advisors, LLC	reduced	-0.06	-251,082	2,221,190	0.95%
2023-09-12	Prosperity Financial Group, Inc.	added	29.56	45,755	323,481	0.28%
2023-09-12	Prosperity Wealth Management, Inc.	added	1.93	-23,380	256,100	0.17%
2023-09-12	Farther Finance Advisors, LLC	added	14.97	21,065	648,487	0.14%
2023-09-08	TUCKER ASSET MANAGEMENT LLC	added	180	267,467	442,877	0.13%

Latest Funds Activity

Are funds buying PFE calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own PFE

No. of Funds

Schedule 13G FIlings of Pfizer

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 09, 2023	vanguard group inc	8.94%	501,636,220	SC 13G/A
Feb 07, 2023	state street corp	5.08%	284,943,697	SC 13G/A
Feb 03, 2023	blackrock inc.	7.9%	442,868,761	SC 13G/A
Feb 14, 2022	state street corp	5.09%	285,771,591	SC 13G/A
Feb 10, 2022	vanguard group inc	8.29%	465,274,925	SC 13G/A
Feb 01, 2022	blackrock inc.	7.3%	409,985,645	SC 13G/A
Feb 12, 2021	state street corp	5.03%	279,831,373	SC 13G
Feb 10, 2021	vanguard group inc	8.06%	447,958,747	SC 13G/A
Jan 29, 2021	blackrock inc.	7.1%	396,973,512	SC 13G/A
Feb 13, 2020	state street corp	5.28%	292,628,794	SC 13G

Recent SEC filings of Pfizer

View All Filings

Date Filed	Form Type	Document
Sep 18, 2023	4	Insider Trading
Sep 18, 2023	4	Insider Trading
Sep 18, 2023	4	Insider Trading
Sep 13, 2023	144	Notice of Insider Sale Intent
Sep 11, 2023	SC 13D/A	13D - Major Acquisition
Sep 01, 2023	4	Insider Trading
Sep 01, 2023	4	Insider Trading
Sep 01, 2023	4	Insider Trading
Aug 16, 2023	4	Insider Trading
Aug 16, 2023	4	Insider Trading

PFE Fair Value

Loading...

Peers (Alternatives to Pfizer)

View All Peers In Detail

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
LLY	512.5B	29.5B	3.56%	89.32%	78.88	17.36	1.53%	14.16%
JNJ	423.3B	97.8B	-2.65%	0.10%	32.43	4.33	2.29%	-28.92%
MRK	272.8B	58.3B	-2.13%	26.48%	17.88	4.63	2.00%	-81.24%
PFE	189.8B	77.9B	-9.16%	-24.26%	8.84	2.44	-23.04%	-26.74%
BMY	150.1B	45.2B	-5.06%	-15.06%	23.72	3.25	-4.15%	20.34%
MID-CAP
RETA	6.5B	-	1.75%	544.26%	-74.04	4.1K	-86.94%	71.24%
PRGO	4.5B	4.6B	-11.49%	-16.32%	-66.69	0.98	6.60%	42.04%
SMALL-CAP
TLRY	1.9B	627.1M	-7.75%	-1.79%	-1.34	3.1	-0.20%	-204.67%
SUPN	1.5B	634.0M	-11.88%	-19.94%	34.62	2.37	0.62%	-24.59%
INVA	832.3M	244.3M	-4.13%	4.68%	4.22	3.41	-39.50%	-4.99%
CRON	830.8M	109.5M	21.79%	-27.57%	-5.79	7.59	-2.66%	-32.13%
CGC	480.0M	453.3M	110.37%	-71.69%	-0.39	1.06	-16.04%	55.90%
ACRS	479.1M	31.2M	-7.77%	-52.62%	-4.55	15.37	407.54%	-26.47%
OCUL	269.4M	54.6M	-13.04%	-44.44%	-2.97	4.93	9.39%	-179.16%
ENDP	-	2.2B	-	-	-	-	-22.39%	63.59%

Pfizer News

Returns for PFE

Cumulative Returns on PFE

4.9%

10-Year Cumulative Returns

3.1%

7-Year Cumulative Returns

-2.3%

5-Year Cumulative Returns

-0.2%

3-Year Cumulative Returns

Risks for PFE

What is the probability of a big loss on PFE?

56.1%

Probability that Pfizer stock will be more than 20% underwater in next one year

11.5%

Probability that Pfizer stock will be more than 30% underwater in next one year.

0%

Probability that Pfizer stock will be more than 40% underwater in next one year.

*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does PFE drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Pfizer was unfortunately bought at previous high price.

Drawdowns

Financials for Pfizer

Income Statement (Last 12 Months)
(In Millions)

(*) denotes actual numbers (not divided by Millions)
Income Statement (Last 12 Months)																					(In Millions)
Description	(%) Q/Q	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3	2018Q2
Revenue	-16.1%	77,944	92,952	100,330	99,879	101,276	92,433	81,288	68,877	55,119	46,084	41,651	32,067	34,470	37,870	40,905	40,217	40,835	41,037	40,825	53,373	53,243
S&GA Expenses	3.1%	14,951	14,502	13,677	13,136	12,644	12,519	12,703	12,338	12,097	11,833	11,597	10,474	11,076	11,928	12,726	12,274	12,508	12,539	12,612	15,003	15,013
EBITDA	-100.0%	-	33,357	36,171	34,708	33,956	34,344	30,969	-	-	18,239	13,819	8,775	17,376	18,477	18,827	25,371	18,628	-	-	-	-
EBITDA Margin	-100.0%	-	0.36*	0.36*	0.35*	0.34*	0.37*	0.38*	-	-	0.45*	0.33*	0.20*	0.37*	0.36*	0.36*	0.48*	0.35*	-	-	-	-
Interest Expenses	6.0%	1,492	1,408	1,442	1,383	1,440	1,475	1,467	1,549	1,529	1,614	1,641	1,638	1,688	1,674	1,587	1,589	1,396	1,437	1,311	1,385	1,361
Earnings Before Taxes	-28.7%	22,771	31,949	34,729	33,325	32,167	27,669	24,311	21,082	13,809	9,886	7,036	-1,431	8,726	9,841	11,321	9,954	3,404	3,790	3,594	13,785	13,193
EBT Margin	-100.0%	-	0.34*	0.35*	0.33*	0.32*	0.30*	0.30*	0.30*	0.24*	0.30*	0.18*	0.03*	0.21*	0.22*	0.22*	-	-	-	-	-	-
Net Income	-26.1%	21,472	29,051	31,372	29,771	29,309	24,966	21,979	19,432	12,755	10,681	9,159	7,730	13,941	15,498	16,026	16,217	12,651	11,477	11,153	23,821	22,547
Net Income Margin	-100.0%	-	0.31*	0.31*	0.30*	0.29*	0.27*	0.27*	0.28*	0.23*	0.26*	0.22*	0.18*	0.30*	0.31*	0.31*	-	-	-	-	-	-
Free Cashflow	-100.0%	-	20,206	26,031	23,362	28,443	31,783	29,869	29,814	21,141	13,451	12,151	10,566	12,892	11,962	10,516	-	-	-	-	-	-

Balance Sheet
(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3	2018Q2
Assets	12.6%	220,168	195,617	197,000	195,350	195,290	183,841	181,000	179,188	169,920	158,818	154,000	178,983	178,000	166,336	167,594	170,446	156,199	155,421	159,000	168,000	164,980
Current Assets	46.5%	73,347	50,078	51,259	70,403	67,466	54,420	59,693	57,900	48,814	39,533	35,067	47,739	46,424	34,738	32,803	33,459	47,073	45,290	49,926	41,583	37,303
Cash Equivalents	21.5%	2,632	2,166	416	1,298	1,824	2,513	1,983	2,034	2,418	1,809	1,825	1,627	1,845	2,196	1,350	2,846	1,837	2,018	1,225	3,658	2,811
Inventory	8.1%	10,310	9,541	8,981	9,513	10,454	9,979	9,059	8,640	8,948	8,493	8,020	9,295	8,564	8,423	7,068	8,222	8,233	8,029	7,508	8,184	8,074
Net PPE	2.6%	17,488	17,052	16,274	15,441	15,244	15,109	14,882	14,436	14,224	14,011	13,745	14,403	14,113	14,040	12,969	13,701	13,521	13,467	13,385	14,036	13,919
Goodwill	0.2%	51,572	51,476	51,375	795	49,891	50,211	49,208	49,489	49,867	49,791	49,556	59,902	58,449	58,502	48,181	58,665	53,352	53,487	42,927	55,614	55,836
Liabilities	28.1%	120,875	94,381	101,288	102,459	107,821	101,155	104,013	103,221	99,605	89,953	90,756	113,487	113,370	100,998	104,148	105,051	96,274	96,263	95,664	96,174	94,856
Current Liabilities	-5.2%	34,647	36,562	42,138	44,314	47,410	39,268	42,671	41,803	35,664	26,652	25,920	34,154	32,723	33,890	37,304	36,974	32,030	29,423	31,858	29,013	32,156
LT Debt, Current	-0.1%	3,565	3,567	2,560	2,566	1,276	260	1,636	2,663	3,687	3,676	2,002	2,149	1,481	337	1,462	2,431	2,139	4,471	4,776	4,255	4,262
LT Debt, Non Current	93.5%	61,356	31,704	32,884	32,629	34,294	35,656	36,000	36,250	35,354	35,347	37,133	49,785	50,529	36,281	35,955	36,044	36,168	35,733	32,909	33,652	28,935
Shareholder's Equity	-2.2%	99,019	101,236	95,661	92,631	87,469	82,685	77,462	75,967	70,315	68,865	63,473	65,503	64,570	65,341	63,447	65,396	59,924	59,158	63,758	71,664	70,124
Retained Earnings	-1.8%	128,796	131,102	125,656	122,967	116,608	111,193	103,394	102,252	96,346	95,158	90,392	100,284	100,203	101,000	97,670	100,113	94,440	93,388	89,574	91,995	89,860
Additional Paid-In Capital	0.2%	92,329	92,153	91,802	91,359	91,183	90,844	90,591	89,973	89,336	89,002	88,674	88,161	87,886	87,680	87,428	87,099	86,963	86,635	86,253	85,828	84,898
Accumulated Depreciation	0.3%	15,554	15,514	15,174	14,931	14,969	15,358	15,074	15,403	15,328	15,105	14,812	16,636	16,889	16,929	16,789	16,728	16,389	16,158	16,591	17,078	16,844
Shares Outstanding	0.2%	5,646	5,634	-	5,607	5,593	5,617	-	5,609	5,598	5,584	-	5,557	5,554	5,545	-	5,545	5,562	5,635	-	5,875	5,866
Minority Interest	3.0%	274	266	256	259	261	261	262	275	273	245	235	236	228	312	303	293	357	352	351	346	346

Cashflow (Last 12 Months)
(In Millions)

(*) denotes actual numbers (not divided by Millions)
Cashflow (Last 12 Months)																					(In Millions)
Description	(%) Q/Q	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3	2018Q2
Cashflow From Operations	-39.2%	14,560	23,938	29,267	26,599	31,454	34,583	32,580	32,291	23,552	15,808	14,403	12,547	14,967	14,023	12,588	13,557	14,306	15,542	15,827	18,178	17,808
Share Based Compensation	-15.6%	752	891	872	1,004	1,162	1,096	1,182	973	904	870	755	707	547	559	687	689	928	926	923	927	831
Cashflow From Investing	-108.7%	-27,207	-13,035	-15,783	-13,959	-23,408	-20,232	-22,546	-11,630	-1,073	-5,947	-4,271	-15,434	-22,675	-11,566	-3,945	-1,876	1,980	2,408	4,525	530	423
Cashflow From Financing	223.6%	13,627	-11,027	-14,834	-13,170	-8,510	-13,587	-9,816	-20,252	-21,972	-10,256	-9,649	1,698	7,792	-2,218	-8,485	-12,452	-17,131	-18,188	-20,441	-17,777	-18,082
Buy Backs	-	-	-	2,000	2,000	2,000	2,000	-	-	-	-	-	-	-	-	8,865	13,895	15,000	15,000	12,198	7,168	6,063

PFE Income Statement

2023-07-02

CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED) - USD ($)
shares in Millions, $ in Millions

3 Months Ended

6 Months Ended

Jul. 02, 2023

Jul. 03, 2022

Jul. 02, 2023

Jul. 03, 2022

Income Statement [Abstract]

Revenues

$ 12,734

$ 27,742

$ 31,015

$ 53,402

Costs and expenses:

Cost of sales

^[1]

3,237

8,648

8,122

18,632

Selling, informational and administrative expenses

^[1]

3,497

3,048

6,914

5,642

Research and development expenses

^[1]

2,648

2,815

5,153

5,116

Acquired in-process research and development expenses

33

1

55

356

Amortization of intangible assets

1,184

822

2,287

1,657

Restructuring charges and certain acquisition-related costs

214

189

222

381

Other (income)/deductions––net

(347)

772

(277)

1,122

Income from continuing operations before provision/(benefit) for taxes on income

^[2]

2,269

11,447

8,539

20,497

Provision/(benefit) for taxes on income

(71)

1,570

644

2,742

Income from continuing operations

2,340

9,877

7,895

17,756

Discontinued operations––net of tax

(2)

34

(1)

26

Net income before allocation to noncontrolling interests

2,338

9,911

7,894

17,781

Less: Net income attributable to noncontrolling interests

11

6

24

12

Net income attributable to Pfizer Inc. common shareholders

$ 2,327

$ 9,906

$ 7,870

$ 17,769

Earnings per common share––basic:

Income from continuing operations attributable to Pfizer Inc. common shareholders (in dollars per share)

$ 0.41

$ 1.76

$ 1.40

$ 3.17

Discontinued operations––net of tax (in dollars per share)

0

0.01

0

Net income attributable to Pfizer Inc. common shareholders (in dollars per share)

0.41

1.77

1.40

3.17

Earnings per common share––diluted:

Income from continuing operations attributable to Pfizer Inc. common shareholders (in dollars per share)

0.41

1.73

1.38

3.09

Discontinued operations––net of tax (in dollars per share)

0

0.01

0

Net income attributable to Pfizer Inc. common shareholders (in dollars per share)

$ 0.41

$ 1.73

$ 1.38

$ 3.10

Weighted-average shares––basic

5,646

5,593

5,640

5,605

Weighted-average shares––diluted

5,713

5,712

5,720

5,735

[1]

Exclusive of amortization of intangible assets.

[2]

Income from continuing operations before provision/(benefit) for taxes on income. Biopharma’s earnings include dividend income from our investment in ViiV of $91 million in the second quarter of 2023 and $69 million in the second quarter of 2022, and $183 million in the first six months of 2023 and $125 million in the first six months of 2022. In connection with the organizational changes effective in the third quarter of 2022, certain functions transferred between Biopharma and corporate enabling functions and certain activities were realigned within the GPD organization. We have reclassified $58 million of costs in the second quarter of 2022 and $105 million in the first six months of 2022 from corporate enabling functions, which are included in Other business activities, to Biopharma to conform to the current period presentation.

PFE Balance Sheet

2023-07-02

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Millions

Jul. 02, 2023

Dec. 31, 2022

Assets

Cash and cash equivalents

$ 2,632

$ 416

Short-term investments

42,153

22,316

Trade accounts receivable, less allowance for doubtful accounts: 2023—$471; 2022—$449

10,231

10,952

Inventories

^[1]

10,310

8,981

Current tax assets

3,194

3,577

Other current assets

4,828

5,017

Total current assets

73,347

51,259

Equity-method investments

11,422

11,033

Long-term investments

3,644

4,036

Property, plant and equipment, less accumulated depreciation: 2023—$15,554; 2022—$15,174

17,488

16,274

Identifiable intangible assets

^[2]

41,406

43,370

Goodwill

51,572

51,375

Noncurrent deferred tax assets and other noncurrent tax assets

8,261

6,693

Other noncurrent assets

13,028

13,163

Total assets

220,168

197,205

Liabilities and Equity

Short-term borrowings, including current portion of long-term debt: 2023—$3,565; 2022—$2,560

3,985

2,945

Trade accounts payable

6,081

6,809

Dividends payable

2,315

2,303

Income taxes payable

2,928

1,587

Accrued compensation and related items

1,972

3,407

Deferred revenues

1,286

2,520

Other current liabilities

16,079

22,568

Total current liabilities

34,647

42,138

Long-term debt

61,356

32,884

Pension and postretirement benefit obligations

2,184

2,250

Noncurrent deferred tax liabilities

1,232

1,023

Other taxes payable

8,052

9,812

Other noncurrent liabilities

13,403

13,180

Total liabilities

120,875

101,288

Commitments and Contingencies

Common stock

478

476

Additional paid-in capital

92,329

91,802

Treasury stock

(114,482)

(113,969)

Retained earnings

128,796

125,656

Accumulated other comprehensive loss

(8,102)

(8,304)

Total Pfizer Inc. shareholders’ equity

99,019

95,661

Equity attributable to noncontrolling interests

274

256

Total equity

99,293

95,916

Total liabilities and equity

$ 220,168

$ 197,205

[1]	The increase from December 31, 2022 reflects higher inventory levels for Paxlovid and, to a lesser extent, increases for certain products due to supply recovery and inventory build, partially offset by decreases due to net market demand.
[2]	The decrease is primarily due to amortization expense of $2.3 billion and impairments of $248 million (see Note 4), partially offset by additions of $681 million mostly related to milestone payments for the approvals in the U.S. for Zavzpret nasal spray and Ngenla.

About Pfizer

Albert Bourla

www.pfizer.com

65535

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Market Summary

PFE Alerts

PFE Stock Price

PFE RSI Chart

PFE Valuation

PFE Price/Sales (Trailing)

PFE Profitability

PFE Fundamentals

PFE Revenue

PFE Earnings

Price Action

52 Week Range

PFE Financial Health

PFE Investor Care

Historical Charts for Stock Metrics

Latest Insider Trading transactions for PFE

Which funds bought or sold PFE recently?

Latest Funds Activity

PFE Alerts

Schedule 13G FIlings of Pfizer

Recent SEC filings of Pfizer

PFE Fair Value

Peers (Alternatives to Pfizer)

Pfizer News

Returns for PFE

Cumulative Returns on PFE

Risks for PFE

What is the probability of a big loss on PFE?

How does PFE drawdown profile look like?

Financials for Pfizer

Income Statement (Last 12 Months).css-zgnqz2{margin:0;font-family:"Roboto","Helvetica","Arial",sans-serif;font-weight:400;font-size:0.75rem;line-height:1.66;letter-spacing:0.03333em;color:#595959;}(In Millions)

Balance Sheet(In Millions)

Cashflow (Last 12 Months)(In Millions)

PFE Income Statement

PFE Balance Sheet

About Pfizer

Income Statement (Last 12 Months)
(In Millions)

Balance Sheet
(In Millions)

Cashflow (Last 12 Months)
(In Millions)